The data for TFAM are also consistent with data from other researchers who show that TFAM and PGC1α levels are reduced in the acquired cisplatin resistant ovarian clear-cell carcinoma subline SKOV-3-R when compared to parental controls [41]. The gene discussed is PPARGC1A; the disease is ovarian clear cell cancer.